Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.
Exscientia Plc (EXAI) is a pioneer in AI-driven drug discovery, transforming pharmaceutical research through automated small molecule design. This page serves as the definitive source for tracking the company's latest developments, offering investors and industry observers timely updates on its groundbreaking work.
Access comprehensive coverage of financial results, research milestones, and strategic partnerships that define Exscientia's progress. Our curated news collection includes press releases on clinical advancements, technology innovations, and regulatory developments essential for understanding the company's trajectory.
Key updates feature Exscientia's AI-optimized drug candidates, collaborations with leading pharmaceutical organizations, and insights into their automated discovery platform. The resource is particularly valuable for tracking how machine learning accelerates compound design while maintaining rigorous quality standards.
Bookmark this page for efficient monitoring of Exscientia's contributions to biopharmaceutical innovation. Return regularly to stay informed about how their AI-first approach continues to reshape drug development timelines and methodologies.
Exscientia plc (Nasdaq: EXAI) reported significant advancements in its pipeline and financial results for 2021. Key highlights include 11 new programmes added, a $100 million upfront payment from Sanofi focused on oncology and immunology, and the achievement of preclinical milestones in collaborations with Bayer and Bristol Myers Squibb. Financially, the company generated $36.9 million in revenue, a $23.9 million increase year-over-year, with $85.3 million cash flow from collaborations. As of year-end, cash reserves stood at $758.9 million, positioning the company for future growth.
Exscientia (NASDAQ: EXAI) will announce its financial results for Q4 and the full year ended December 31, 2021, on March 23, 2022, after market close. A conference call is scheduled for March 24, 2022, at 12:30 p.m. GMT / 8:30 a.m. ET to discuss the results and showcase their AI-driven drug discovery platform. Exscientia is at the forefront of automating the drug development process, with over 25 projects in progress, aiming to transform scientific concepts into therapeutic candidates efficiently.
Rallybio Corporation (Nasdaq: RLYB) reported its 2021 financial results, highlighting a net loss of $47 million and increased R&D expenses of $26.9 million, driven by advancements in product candidates. The company is progressing with Phase 1 studies for RLYB212, targeting FNAIT, and RLYB116 for complement-related diseases, with initial data expected in 2022. Rallybio's cash position stood at $175.3 million as of December 31, 2021, supporting ongoing development efforts.
Exscientia (NASDAQ: EXAI) has partnered with the University of Oxford Target Discovery Institute to launch the Xcellomics program aimed at revolutionizing early-stage drug discovery.
By sourcing cellular functional assays from academic researchers, Xcellomics seeks to identify novel therapeutic candidates while leveraging Exscientia's AI capabilities.
The program, starting with oncology, will evaluate submissions for collaborative development, emphasizing shared data ownership between researchers and Xcellomics.
Exscientia (NASDAQ: EXAI) has announced the acceptance of three abstracts for presentation at the upcoming AACR Annual Meeting 2022 in New Orleans, showcasing the potential of its AI-driven drug discovery platform.
The abstracts focus on innovations such as targeting adenosine antagonist patient responses and profiling GTAEXS-617, a potent inhibitor of CDK7. These advances aim to improve patient outcomes in oncology by identifying responsive patient groups and enhancing drug design.
Symbotic LLC announced its fiscal Q1 2022 results, reporting revenue of $77.1 million, a significant increase from $5.5 million in Q1 2021. The adjusted EBITDA was ($21.3) million with a net income of ($23.1) million. Gross margin improved to 18.8% from (10.2)% year-over-year. The company's backlog stands at $5.3 billion. Symbotic is in a proposed business combination with SVF Investment Corp. 3, aiming for Nasdaq listing. CEO Rick Cohen highlighted rapid scaling and client deployments as key growth drivers.
Exscientia (Nasdaq: EXAI) announced participation of CEO Andrew Hopkins and CFO Ben Taylor in fireside chats at two upcoming investor conferences. The Morgan Stanley EMEA HealthTech Conference is scheduled for March 1, 2022, at 9:00 a.m. ET. The Barclays Global Healthcare Conference will take place on March 16, 2022, at 11:15 a.m. ET. Live webcasts will be available on the company’s website, with archived replays accessible for 30 days post-event. Exscientia is focused on AI-driven drug discovery with over 25 projects in its pipeline.
Exscientia has appointed Professor Charlotte Deane as Chief Scientist of Biologics AI, enhancing its leadership in AI-driven drug development. Deane, a prominent bioinformatician from the University of Oxford, will leverage her 20+ years of experience to integrate AI and protein structure design in creating new drug candidates. This strategic move is expected to accelerate Exscientia's mission to expedite medicine development. She will retain her academic roles while contributing to Exscientia’s innovative projects, which include ongoing advancements in AI-designed therapeutics.
Exscientia has announced a significant collaboration with Sanofi to develop up to 15 novel small molecule candidates targeting oncology and immunology. This agreement utilizes Exscientia's AI-driven platform to improve drug discovery, integrating patient samples for more effective candidate selection. Exscientia will receive an upfront payment of
Rallybio Corporation (NASDAQ: RLYB) announced that the first subjects have been dosed in the Phase 1 study of RLYB212, targeting fetal and neonatal alloimmune thrombocytopenia (FNAIT). A proof-of-concept study is anticipated in Q3 2022. Additionally, they are set to initiate a Phase 1 study of RLYB116, a C5 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH) and generalized Myasthenia Gravis (gMG), in Q1 2022. The company is also advancing an ENPP1 inhibitor with IND-enabling studies expected in Q2 2022, enhancing their commitment to developing therapies for severe and rare diseases.
FAQ
What is the current stock price of Exscientia Plc (EXAI)?
What is the market cap of Exscientia Plc (EXAI)?
